Market Research Logo

Lewy body Dementia - Pipeline Review, H2 2016

Lewy body Dementia - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Lewy body Dementia - Pipeline Review, H2 2016’, provides an overview of the Lewy body Dementia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lewy body Dementia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lewy body Dementia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Lewy body Dementia
    • The report reviews pipeline therapeutics for Lewy body Dementia by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Lewy body Dementia therapeutics and enlists all their major and minor projects
    • The report assesses Lewy body Dementia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Lewy body Dementia
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Lewy body Dementia
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Lewy body Dementia pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Lewy body Dementia Overview
    Therapeutics Development
    Pipeline Products for Lewy body Dementia - Overview
    Lewy body Dementia - Therapeutics under Development by Companies
    Lewy body Dementia - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Lewy body Dementia - Products under Development by Companies
    Lewy body Dementia - Companies Involved in Therapeutics Development
    Axovant Sciences Ltd.
    BioArctic AB
    Eisai Co., Ltd.
    Immungenetics AG
    Sumitomo Dainippon Pharma Co., Ltd.
    Takeda Pharmaceutical Company Limited
    Lewy body Dementia - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    (donepezil hydrochloride + glycopyrrolate) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (glycopyrrolate + rivastigmine) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BAN-0805 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    E-2027 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    intepirdine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nelotanserin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Activate ABC Transporter for Neurodegeneration Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Agonize M1 Muscarinic Acetylcholine Receptor for Lewy Body Dementia and Parkinson's Disease Dementia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TAK-071 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TAK-915 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    zonisamide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Lewy body Dementia - Dormant Projects
    Lewy body Dementia - Product Development Milestones
    Featured News & Press Releases
    Apr 21, 2016: FAU site for first US clinical trial for Lewy Body dementia
    Feb 09, 2016: Axovant Sciences Announces Launch Of First-In-Class Clinical Programs Of RVT-101 For Lewy Body Dementia
    Feb 09, 2016: Axovant Sciences Announces Launch Of First-In-Class Clinical Programs Of Nelotanserin For Lewy Body Dementia
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Lewy body Dementia, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Lewy body Dementia - Pipeline by Axovant Sciences Ltd., H2 2016
    Lewy body Dementia - Pipeline by BioArctic AB, H2 2016
    Lewy body Dementia - Pipeline by Eisai Co., Ltd., H2 2016
    Lewy body Dementia - Pipeline by Immungenetics AG, H2 2016
    Lewy body Dementia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
    Lewy body Dementia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Lewy body Dementia - Dormant Projects, H2 2016
    List of Figures
    Number of Products under Development for Lewy body Dementia, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report